227 related articles for article (PubMed ID: 24638135)
1. Alzheimer disease: Lessons from immunotherapy for Alzheimer disease.
Wang YJ
Nat Rev Neurol; 2014 Apr; 10(4):188-9. PubMed ID: 24638135
[No Abstract] [Full Text] [Related]
2. Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo A; Lopera F
Colomb Med (Cali); 2016 Dec; 47(4):203-212. PubMed ID: 28293044
[TBL] [Abstract][Full Text] [Related]
3. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
4. [Current status of Alzheimer's disease immunotherapy and pharmacologic effect of BAN2401.].
Araki S
Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):21-5. PubMed ID: 20628209
[No Abstract] [Full Text] [Related]
5. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
van Dyck CH
Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
Li Y; Liu Y; Wang Z; Jiang Y
Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
[TBL] [Abstract][Full Text] [Related]
7. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer disease immunotherapeutics: then and now.
Jindal H; Bhatt B; Sk S; Singh Malik J
Hum Vaccin Immunother; 2014; 10(9):2741-3. PubMed ID: 25483498
[TBL] [Abstract][Full Text] [Related]
9. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O; Skrabana R; Revajova V; Novak M
Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer disease. Could anti-amyloid-β immunotherapy do more harm than good?
Wood H
Nat Rev Neurol; 2016 Jan; 12(1):2. PubMed ID: 26610710
[No Abstract] [Full Text] [Related]
11. Bapineuzumab.
Kerchner GA; Boxer AL
Expert Opin Biol Ther; 2010 Jul; 10(7):1121-30. PubMed ID: 20497044
[TBL] [Abstract][Full Text] [Related]
12. [Amyloid-beta protein vaccine therapy for alzheimer's disease].
Hara H
Nihon Naika Gakkai Zasshi; 2006 Jun; 95(6):1122-8. PubMed ID: 16846064
[No Abstract] [Full Text] [Related]
13. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
14. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
Panza F; Lozupone M; Dibello V; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
Immunotherapy; 2019 Jan; 11(1):3-6. PubMed ID: 30702009
[No Abstract] [Full Text] [Related]
15. Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target.
Wang Y; Yan T; Lu H; Yin W; Lin B; Fan W; Zhang X; Fernandez-Funez P
Neurodegener Dis; 2017; 17(6):242-250. PubMed ID: 28787714
[TBL] [Abstract][Full Text] [Related]
16. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
Solomon B
Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
[TBL] [Abstract][Full Text] [Related]
17. Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.
Montoliu-Gaya L; Villegas S
Expert Rev Mol Med; 2016 Jun; 18():e13. PubMed ID: 27357999
[TBL] [Abstract][Full Text] [Related]
18. [Adaptive immunity to Aβ amyloid peptide in Alzheimer's disease: lessons and perspectives].
Dorothée G; Aucouturier P
Med Sci (Paris); 2011 Nov; 27(11):938-40. PubMed ID: 22130019
[No Abstract] [Full Text] [Related]
19. Value in development of a TAPIR-like mouse monoclonal antibody to Abeta.
Sambamurti K; Pappolla MA; Jagannatha Rao KS
J Alzheimers Dis; 2008 Jun; 14(2):175-7. PubMed ID: 18663823
[No Abstract] [Full Text] [Related]
20. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I.
Agadjanyan MG; Cribbs DH
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
